ELAN · Elanco Animal Health Incorporated

conf –

enthusiasm:9.0 · trend:8 · quantifies:0 · impact:0 · under_radar:0 · credibility:0 · business_impact:0 · disruption:0 · confirmation:0

Enthusiasm latest 3 / prev 2 (rising)

Elanco's AI narrative is thin and entirely subsumed within the Elanco Ascend cost-productivity program, with no AI-specific financial metrics disclosed in either call. The most concrete disclosure — an automated order-to-cash tool — is framed as process modernization rather than a quantified cost or revenue driver, and no figures are attached. Credibility is low: management uses 'comprehensive AI agenda' language in Q1 FY2026 but has yet to translate it into any measurable business impact for investors.

• Q1 FY2026 — Bob VanHimbergen: 'we recently implemented an automated sales order tool that modernizes the order-to-cash process. This initiative enhances fulfillment accuracy and accelerates order cycles leading to improved cash flow visibility and lower operational costs.'

• Q1 FY2026 — Bob VanHimbergen: 'Elanco Ascend is integrating automation and AI across our entire value chain to accelerate our innovation pipeline, enhance manufacturing quality and drive sales through deeper data-driven customer insights.'
• Q4 FY2025 — Bob VanHimbergen: 'our teams are actively advancing key AI, operational and procurement initiatives'

• Q1 FY2026 — Bob VanHimbergen: 'Our comprehensive AI agenda also includes leveraging AI-driven automation to transform legacy processes as part of Ascend.'
• Q1 FY2026 — Jeff Simmons: 'AI accelerates what we can learn' as diagnostic detection expands across the growing pet health market.
• Q4 FY2025 — Bob VanHimbergen: AI, operational and procurement initiatives 'are expected to result in both P&L and cash flow benefits.'

Est. revisions rising  ·  Fwd P/E 27.5  ·  EV/Sales 3.3x

AI claim maps to Pet Health, Farm Animal, Cattle

3/10 qualitative impact   limited  medium-term · soft evidence

Where AI matters: Ascend cost productivity and order-to-cash ops

Only credible deployment cited is an automated order-to-cash tool under Elanco Ascend; broader value-chain and pipeline AI language is aspirational with no quantified P&L, revenue, or product impact.

Caveats: Upside may be indistinguishable generic cost saves within Ascend with no AI-specific KPIs; Competitor AI-accelerated R&D could narrow innovation gaps over time; Management rhetoric on a comprehensive AI agenda outruns disclosed scale and metrics

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 2/10

Core economics are regulated animal-health Rx/vaccines and channel relationships, not billable hours or easily AI-substituted content; AI may aid internal efficiency and discovery but does not plausibly commoditize approved medicines or Elanco's pricing model near term.

option liquidity: fair

proxy inputs — dollar-ADV $152M · beta 1.687 · px $25.70

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.